Overview of Vaccines

Applied Biochemistry and Biotechnology - Part B Molecular Biotechnology

Volumn 8, Issue 2, 1997, Pages 123-134

  Ada, Gordon ^a  

^a Biology and Environment   (Australia)

Author keywords

Chimeric live vectors; Disease eradication; DNA plasmids; Efficacy; Immune response manipulation; Oligopeptides; Safety; Vaccination; Vaccine administration; Vaccines

Indexed keywords

BACTERIA (MICROORGANISMS); CORYNEBACTERINEAE; HEPATITIS B VIRUS; MAMMALIA; VARIOLA VIRUS;

DNA VACCINE; INACTIVATED VACCINE; LIVE VACCINE; PEPTIDE; VACCINE;

ANIMAL; BIOTECHNOLOGY; CHEMISTRY; CLASSIFICATION; GENE VECTOR; GENETIC TRANSFECTION; HUMAN; IMMUNE SYSTEM; IMMUNOLOGY; INFECTION; LYMPHOCYTE; METHODOLOGY; MICROBIOLOGY; PHYSIOLOGY; REVIEW;

ANIMALS; BIOTECHNOLOGY; GENETIC VECTORS; HUMANS; IMMUNE SYSTEM; INFECTION; LYMPHOCYTES; PEPTIDES; TRANSFECTION; VACCINES; VACCINES, ATTENUATED; VACCINES, DNA; VACCINES, INACTIVATED;

EID: 0031242317     PISSN: 10736085     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02752256     Document Type: Review

References (52)

1. Ada, G. and Ramsay, A. (1977) Vaccines, Vaccinations and the Immune Response. Lippincott-Raven, Philadelphia, PA.
2. Cadoz, M., Strady, A., Meigner, B., Taylor, J., Tartaglia, J., Paoletti, E., and Plotkin, S. (1992) Immunization with canarypox virus expressing rabies glycoprotein. Lancet 339, 1429-1432.
3. Clark, H. F. and Offit, P. A. (1994) Rotavirus vaccines, in Vaccines (2nd ed.) (Plotkin, S. A. and Mortimer, E. A., eds.), Saunders, Philadelphia, PA, pp. 809-822.
4. Maassab, H. F., Shaw, M. W., and Heilman, C. A. (1994) Live influenza virus vaccines, in Vaccines (2nd ed.) (Plotkin, S. A. and Mortimer, E. A., eds.), Saunders, Philadelphia, PA, pp. 781-801.
5. Levine, M. M. (1994) Typhoid fever vaccines, in Vaccines (2nd ed.) (Plotkin, S. A. and Mortimer, E. A., eds.), Saunders, Philadelphia, PA, pp. 597-634.
6. Curtiss, R., III, Kelly, S. M., Tinge, S. A., Tackett, C. O., Levine, M. M., Srinivasan, J., and Koopman, M. (1994) Recombinant Salmonella vectors in vaccine development. Dev. Biol. Stand. 82, 23-33.
7. Tartaglia, J., Perkus, M. E., and Taylor, J. (1992) NYVAC: a highly attenuated strain of vaccinia virus. Virology 188, 217-232.
8. Daniel, M. D., Kirchoff, F., Czajak, S. C., Seghel, O. K., and Desrosiers, R. C. (1992). Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 258, 1938-1940.
9. Mortimer, E. A. (1994) Pertussis vaccine, in Vaccines (2nd ed.) (Plotkin, S. A. and Mortimer, E. A., eds.), Saunders, Philadelphia, PA, pp 91-136.
10. Holmgren, J., Svennerholm, A. M., Clemens, J. D., Sack, D., Black, R., and Levine, M. (1987) An oral B subunit against cholera: from concept to successful field trial. Adv. Exp. Med. Biol. 216B, 1649-1660.
11. Mullbacher, A., Ada, G. L., and Tha Hla, R. (1988) Gamma-irradiated influenza A virus can prime for a cross-reactive and cross-protective immune response against influenza A virus. Immunol. Cell Biol. 66, 153-158.
12. Braciale, T. J. and Yap, K. L. (1978) Role of viral infectivity in the induction of influenza virus-specific cytotoxic T cells. J. Exp. Med. 147, 1236-1252.
13. Flynn, J. N., Keating, P., Hosie, M. J., Mackett, M., Stephens, E. B., Beatty, J. A., Neil, J. C., and Jarrett, O. (1996) Env-specific CTL predominate in cats protected from feline immunodeficiency virus infection by vaccination. J. Immunol. 157, 3658-3665.
14. Hilleman, M. R. (1992) Vaccine perspectives from the vantage of hepatitis B. Vaccine Res. 1, 1-15.
15. Egea, E., Iglesias, A., Salazar, M., Morimoto, C., Kruskall, M. S., Awdeh, Z., Schlossman, F. S., Alper, C. A., and Yunis, E. J. (1991) The cellular basis for lack of antibody response to hepatitis B vaccine in humans. J. Exp. Med. 173, 531-542.
16. Langmuir, I. D., Bregman, D. J., Kurlland, L. D., Nathanson, N., and Vector, M. (1984) An epidemiological and clinical evaluation of Guillain-Barre syndrome reported in association with the administration of swine influenza vaccine. J. Epidemiol. 119, 841-879.
17. Stratton, K. R., Howe, C. J., and Johnston, R. B. (1994) Adverse Events Associated with Childhood Vaccines: Evidence Bearing on Causality. Institute of Medicine, National Academy Press, Washington, DC, pp. 1-464.
18. Galaska, A. M., Lauer, B. A., Henderson, R. H., and Keja, J. (1984) Indications and contra-indications for vaccines used in the Expanded Programme of Immunization. Bull. WHO 62, 357-366.
19. Halsey, N. A. (1993) Increased mortality following high titer measles vaccines: too much of a good thing. Pediat. Infect. Dis. 12, 462-465.
20. Kapikian, A. Z., Mitchell, R. H., and Chanock, R. M. (1969) An epidemiological study of altered clinical reactivity to respiratory syncytial (RS) virus in children previously vaccinated with inactivated RS virus vaccine. Am. J. Epidemiol. 89, 405-421.
21. Expanded Programme of Immunization. Certification of poliomyelitis eradication: the Americas, 1994. (1994) Wk. Epidemiol. Rec. 69, 293-295.
22. Fenner, F. (1984) Viral vectors for vaccines, in New Approaches for Vaccine Development (Bell, R. and Torrigiani, G., eds.), Schwabe, Basel, pp. 187-192.
23. WHO Consultative Group on Poliomyelitis Vaccines. (1984) Report to World Health Organization, Geneva.
24. Ada, G. (1993) Vaccination in third world countries: guest editorial. Curr. Opin. Immunol. 5, 683-686.
25. Measles Elimination by the Year 2000! (1994) EPI Newsletter (vol. 16); Pan American Health Organization, Washington, DC.
26. Douglas, R. G. (1993) The Children's Vaccine Initiative: will it work? J. Inf. Dis. 168, 269-274.
27. Tam, J. P. (1988) Synthetic peptide vaccine design: synthesis and properties of a high density multiple antigenic peptide system. Proc. Nail. Acad. Sci. USA 85, 5409-5413.
28. Pruksakorn, S., Currie, B., Brandt, E., Martin, D., Galbraith, A., Phornphutkin, C., Hunsakunachai, S., Manmontri, A., and Good, M. F. (1994) Towards a vaccine for rheumatic fever: identification of a conserved target epitope on M protein of group A streptococci. Lancet 344, 639-642.
29. Kaumaya, P. T. P., Berndt, K. D., Heidorn, D. B., Trewhella, J., Kezdy, F. J., and Goldberg, E. (1990) Synthesis and biochemical characterization of engineered topographic immunogenic determinants with topology. Biochemistry 29, 13-23.
30. Ramsay, A. J., Husband, A. J., Ramshaw, I. A., Bao, S., Matthaei, K. I., Kochler, G., and Kopf, M. (1994) The role of interleukin 6 in mucosal IgA antibody responses in vivo. Science 264, 561-563.
31. Schoedel, F., Aguado, M.-T., and Lambert, P.-H. (1994) Introduction. Nucleic acid vaccines, plus many other contributions. Vaccine 12, 1491-1550.
32. Boyer, J. D., Ugen, K. E., and Wang, B. (1997) Protection of chimpanzees from high dose heterologous HIV-1 challenge by DNA vaccination. Nature Med. 3, 526-531.
33. Lai, W. C., Pakes, S. P., Ren, K., Lu, Y.-S., and Bennett, M. (1997) Therapeutic effect of DNA immunization of genetically susceptible mice infected with virulent Mycoplasma pulmonis. J. Immunol. 158, 2513-2516.
34. Leung, K.-N. and Ada, G. L. (1982) Different functions of subsets of effector T cells in murine influenza virus infection. Cell Immunol. 67, 312-324.
35. Larson, H. S., Russell, R. G., and Rouse, B. Y. (1983) Recovery from lethal herpes simplex virus type 1 infection is mediated by cytotoxic T lymphocytes. Infect. Immunol. 41, 197-204.
36. Jackson, D. C., Ada, G. L., and Tha Hla, R. (1976) Cytotoxic T cells recognize very early, minor changes in ectromelia virus-infected target cells. Aust. J. Exp. Biol. Med. Sci. 54, 349-363.
37. Zinkernagel, R. M. and Althage, A. (1977) Anti-viral protection by virus-immune cytotoxic T cells: infected target cells are lysed before infectious virus progeny is assembled. J. Exp. Med. 145, 644-651.
38. Geisow, M. J. (1991) Unravelling the mysteries of molecular audit: MHC class I restriction. Tibtech 9, 403,404.
39. Ada, G. L. and McElrath, M. J. (1996) Perspective. HIV-1 vaccine-induced cytotoxic T cell responses: potential role in vaccine efficacy. AIDS Res. Hum. Retrov. 13, 243-248.
40. Taylor, G. (1994) The role of antibody in controlling and/or clearing virus infections, in Strategies in Vaccine Design (Ada, G. L., ed.), R G Landes, Austin, TX, pp. 17-34.
41. Griffin, D. E., Levine, B., Tyor, W. B., and Irani, D. N. (1992) The immune response in viral encephalitis. Semin. Immunol. 4, 111-119.
42. Eichelberger, M., Allan, W., Zijlstra, M., Jaenisch, R., and Doherty, P. C. (1991) Clearance of influenza virus respiratory infection in mice lacking class I major histocompatibility complex-restricted CD8+ T cells. J. Exp. Med. 174, 875-880.
43. Ramshaw, I. A., Ruby, J., Ramsay, A. J., Ada, G., and Karupiah, G. (1992) Expression of cytokines by recombinant vaccinia viruses: a model for studying cytokines in virus infections in vivo. Immunol. Rev. 127, 157-182.
44. Ada, G. L. (1990) The immune response to antigens: the immunological principles of vaccination. Lancet 335, 523-526.
45. Sharma, D. P., Ramsay, A. J., Maguire, D. J., Rolph, M. S., and Ramshaw, I. A. (1996) Interleukin-4 mediates down regulation of antiviral cytokine expression and of cytotoxic T lymphocyte responses, and exacerbates vaccinia virus expression in vivo. J. Virol. 70, 7103-7107.
46. Alfonso, L. C. C., Scharton, T. M., Vieira, J. Q., Wysocka, M., Trinchieri, G., and Scott, P. (1994) The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 263, 235-237.
47. Sun, J. B., Holmgren, J., and Czerkinsky, C. (1994) Cholera toxin B subunit: an efficient trans-mucosal delivery system for induction of peripheral tolerance. Proc. Natl. Acad. Sci. USA 91, 10,795-10,799.
48. Cooper, P. D. (1994) The selective induction of different immune responses by vaccine adjuvants, in Strategies in Vaccine Design (Ada, G. L., ed.), R G Landes, Austin, TX, pp. 129-158.
49. Graham, B. S., Matthews, T. J., Belshe, R. B., Clements, M. L., Dolin, R., Wright, P. F., Gorse, G. G., and Schwartz, D. H. (1993) Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia naive adults. J. Inf. Dis. 167, 533-537.
50. El-Daher, N., Keefer, M. C., Reichnnan, R. C., Dolin, R., and Roberts, N. S. (1993) Persisting immunodeficiency virus type 1 gp160-specific human T lymphocyte responses including CD8+ cytotoxic activity after receipt of envelope vaccines. J. Inf. Dis. 168, 306-313.
51. Leong, K. H., Ramsay, A. J., Moein, M. J., Ramshaw, I. A., and Ruby, J. (1995) Generation of enhanced immune responses by consecutive immunization with DNA and recombinant fowlpox virus, in Vaccines, '95 (Brown, F., Chanock, R., Ginsberg, H., Norrby, E., eds.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, pp. 321-327.
52. Gautam, A. M. and Glynn, P. (1990) Competition between foreign and self proteins in antigen presentation: ovalbumin can inhibit activation of myelin basic protein-specific T cells. J. Immunol. 144, 1177-1180.